Frontage Holdings Corporation (HKG:1521)

Market Cap	1.46B -35.6%
Revenue (ttm)	2.00B +0.7%
Net Income	52.87M +758.8%
EPS	0.03 +745.9%
Shares Out	2.03B
PE Ratio	28.04
Forward PE	10.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	184,000
Open	0.7100
Previous Close	0.7700
Day's Range	0.7100 - 0.7700
52-Week Range	0.7000 - 1.8700
Beta	0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Frontage Holdings

Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services; and bioequivalence and related services, such a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 1,523
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1521

Financial Performance

In 2025, Frontage Holdings's revenue was $256.69 million, an increase of 0.70% compared to the previous year's $254.91 million. Earnings were $6.79 million, an increase of 758.79%.

Financial numbers in USD